Three little nuggets from that PR: "We will con
Post# of 30028
Posted On: 11/25/2014 9:52:04 AM
Three little nuggets from that PR:
"We will continue moving forward with a strategic development plan focused initially on orphan ocular diseases, where we see tremendous potential for MANF. We are hopeful to develop better treatments for patients suffering from diseases that lead to blindness due to an array of medical conditions."
"We firmly believe MANF has blockbuster potential in ophthalmology, neurology, cardiology and metabolic disorders, including diabetes."
"MANF's current lead indication is Retinitis Pigmentosa, and other applications including Parkinson's disease, Diabetes and Wolfram's Syndrome. Additional applications for MANF may include Alzheimer's disease, Traumatic Brain Injury (TBI), myocardial infarction, antibiotic-induced ototoxicity and certain other rare orphan diseases currently under evaluation. "
"We will continue moving forward with a strategic development plan focused initially on orphan ocular diseases, where we see tremendous potential for MANF. We are hopeful to develop better treatments for patients suffering from diseases that lead to blindness due to an array of medical conditions."
"We firmly believe MANF has blockbuster potential in ophthalmology, neurology, cardiology and metabolic disorders, including diabetes."
"MANF's current lead indication is Retinitis Pigmentosa, and other applications including Parkinson's disease, Diabetes and Wolfram's Syndrome. Additional applications for MANF may include Alzheimer's disease, Traumatic Brain Injury (TBI), myocardial infarction, antibiotic-induced ototoxicity and certain other rare orphan diseases currently under evaluation. "
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼